0RKL.LSE Xvivo Perfusion AB
- Market cap
- SEK 7.41B
- P/E
- 837.6x
- P/B
- -
- ROE
- 5.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0RKL.LSE undervalued?
Graham numberThe Graham number of Xvivo Perfusion AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xvivo Perfusion AB fundamental analysis
No fundamental analysis for Xvivo Perfusion AB yet.
Xvivo Perfusion AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clin…
Full company profileXvivo Perfusion AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xvivo Perfusion AB annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 138M | 148M | 188M | 221M | 180M | 258M | 415M | 598M | 822M | 812M | 977M |
| Gross Profit | 89.3M | 98.9M | 130M | 152M | 120M | 157M | 283M | 445M | 551M | 533M | 614M |
| Operating Income | 7.78M | 7.19M | 13.5M | 10.6M | -13.9M | -4.37M | 18.5M | 38.5M | 116M | 93.0M | 105M |
| EBITDA | 16.2M | 22.4M | 20.2M | 16.8M | -43.3M | 39.2M | 39.2M | 36.3M | 273M | 153M | 190M |
| Net Income | 1.50M | 6.26M | 12.7M | 4.94M | -43.7M | 8.15M | 18.4M | 91.8M | 172M | 25.2M | 130M |
| EPS | 0.07 | 0.24 | 0.48 | 0.18 | -1.61 | 0.28 | 0.62 | 3.07 | 5.44 | 0.80 | 4.11 |
| Balance Sheet | |||||||||||
| Total Assets | 350M | 539M | 587M | 634M | 1.15B | 1.54B | 1.73B | 2.20B | 2.40B | 2.37B | 2.59B |
| Total Liabilities | 33.6M | 34.2M | 46.1M | 57.0M | 142M | 257M | 303M | 251M | 246M | 261M | 323M |
| Shareholders' Equity | 316M | 504M | 540M | 578M | 1.01B | 1.29B | 1.43B | 1.95B | 2.16B | 2.11B | 2.27B |
| Cash & Short-term Investments | 24.9M | 195M | 187M | 160M | 354M | 399M | 247M | 546M | 416M | 292M | 313M |
| Total Debt | - | - | - | 5.55M | 7.21M | 5.72M | 10.0M | 31.4M | 34.0M | 238M | 121M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.6M | 22.2M | 23.6M | 29.5M | -12.3M | -12.1M | 27.9M | 46.3M | 111M | 101M | 242M |
| Capital Expenditure | 20.5M | 34.9M | 54.7M | 83.7M | 64.7M | 94.1M | 131M | 43.0M | 70.7M | 93.7M | 103M |
| Free Cash Flow | -7.96M | -12.7M | -31.1M | -54.2M | -76.9M | -106M | -103M | 3.27M | 40.6M | 7.35M | - |
| Ratios | |||||||||||
| ROE | 0.5% | 1.2% | 2.3% | 0.9% | -4.3% | 0.6% | 1.3% | 4.7% | 8.0% | 1.2% | 5.7% |
| ROA | 0.4% | 1.2% | 2.2% | 0.8% | -3.8% | 0.5% | 1.1% | 4.2% | 7.2% | 1.1% | 5.0% |
| Net Profit Margin | 1.1% | 4.2% | 6.8% | 2.2% | -24.3% | 3.2% | 4.4% | 15.4% | 20.9% | 3.1% | 13.3% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x | 0.02x | 0.02x | 0.11x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xvivo Perfusion AB dividends
Xvivo Perfusion AB has not paid dividends in the last 9 fiscal years.
Who owns Xvivo Perfusion AB
- Insiders 8.33%
- Institutions 60.02%
- Public & others 31.65%
- Shares outstanding 26.4M
- Free float 25.1M
Xvivo Perfusion AB company profile
- Company name
- Xvivo Perfusion AB
- Ticker
- 0RKL.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 207
- Fiscal year end
- December
- Address
- Gemenskapens gata 9, Mölndal, Sweden, 431 53
- Phone
- 46 3 17 88 21 50
- Website
- xvivogroup.com
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Xvivo Perfusion AB management
8- Mr. Christoffer RosenbladChief Executive Officer · born 1975
- Mr. Kristoffer NordstromCFO and Senior VP of Corporate Strategy & Business Development · born 1985
- Ms. Lena Hagman B.Sc.COO & Deputy CEO · born 1965
- Ms. Ylva VihojSenior Vice President of Human Resources · born 1970
- Dr. Magnus Nilsson Ph.D.Senior Advisor · born 1956
- Mr. Johan HolmstromSenior Vice President of Commercial Europe & RoW · born 1970
- Mr. Mark ReadeSenior Vice President of North America · born 1963
- Mr. Sachin A. SankholkarSenior Vice President of Strategic Marketing · born 1973